GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Group PLC (LSE:APTA) » Definitions » LT-Debt-to-Total-Asset

Aptamer Group (LSE:APTA) LT-Debt-to-Total-Asset : 0.16 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aptamer Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aptamer Group's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.16.

Aptamer Group's long-term debt to total assets ratio increased from Dec. 2022 (0.00) to Dec. 2023 (0.16). It may suggest that Aptamer Group is progressively becoming more dependent on debt to grow their business.


Aptamer Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aptamer Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Group LT-Debt-to-Total-Asset Chart

Aptamer Group Annual Data
Trend Mar19 Mar20 Jun22 Jun23
LT-Debt-to-Total-Asset
- 0.02 0.09 0.28

Aptamer Group Semi-Annual Data
Mar19 Mar20 Dec21 Jun22 Dec22 Jun23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial - 0.09 - 0.28 0.16

Aptamer Group LT-Debt-to-Total-Asset Calculation

Aptamer Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (A: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2023 )/Total Assets (A: Jun. 2023 )
=0.764/2.753
=0.28

Aptamer Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0.644/3.968
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptamer Group  (LSE:APTA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Aptamer Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aptamer Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Group (LSE:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Innovation Way, Windmill House, York, GBR, YO10 5BR
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses: Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics.

Aptamer Group (LSE:APTA) Headlines

No Headlines